1	C	OMPENSATED HYPOGONADISM IN MEN WITH SICKLE CELL DISEASE
2		
3		Anna Paloma Martins Rocha Ribeiro ¹
4		Carolina Santos Silva
5		Jean Carlos Zambrano
6		Juliana de Oliveira Freitas Miranda
7		Carlos Augusto Fernandes Molina
8		Cristiano Mendes Gomes
9		Eduardo de Paula Miranda
10		José de Bessa Júnior ²
11		
12	1.	Department of Public Health and Epidemiology, Feira de Santana, Bahia,
13		Brazil.
14		Division of Hematology, Medical School, State University of Feira de Santana,
15		Feira de Santana, Bahia, Brazil
16	2.	Division of Urology, Medical School, São Paulo University, Sao Paulo, Sao
17		Paulo, Brazil
18		
19	3.	Department of Surgery, Ribeirao Preto Medical School, University of Sao
20		Paulo, Ribeirao Preto, Sao Paulo, Brazil
21		
22	4.	Division of Urology, Medical School, Federal University of Ceara, Fortaleza,
23		Ceara, Brazil
24	5.	Division of Urology, Medical School, State University of Feira de Santana,
25		Feira de Santana, Bahia, Brazil
26		

28 ABSTRACT

29

30 Introduction: Sickle cell disease (SCD) is associated with the development of hypogonadism, but there is still controversy regarding its etiology and clinical 31 32 implications. **Objective:** To evaluate the prevalence of hypogonadism in a population of men with SCD and characterize its etiology. Methods: We performed a cross-33 sectional study of 34 men with SCD aged > 18 years. Sociodemographic and clinical 34 35 data, including anthropometric measurements (weight, height, and BMI), were obtained. Early morning blood samples were collected and total testosterone (TT), 36 37 free testosterone (FT), luteinizing hormone (LH), follicle-stimulating hormone (FSH), a complete blood count, and hemoglobin electrophoresis were measured. Results: 38 Median age was 33 [26-41] years, and SS genotype was the most frequent (73.5%). 39 The prevalence of eugonadism, compensated, and secondary hypogonadism was 40 67.5%, 26.4%, and 5.88%, respectively. No men with primary hypogonadism were 41 42 identified in our sample. Those with compensated hypogonadism had also higher 43 FSH levels than individuals with eugonadism; p < 0.001). Conclusion: In our study 44 population of men with SCD a high prevalence of compensated hypogonadism was 45 identified, which is a controversial and distinct clinical entity that warrants monitoring 46 and further research.

47

48 Keywords: sickle cell disease, compensated hypogonadism, testosterone

4

50 INTRODUCTION

51

Sickle cell disease (SCD) is a relatively common genetic disease and 52 53 comprises a group of disorders characterized by the presence of at least one 54 hemoglobin S (1). The sickle gene mutation is common in sub-Saharan Africa and 55 other parts of the world and it is estimated that more than 300 000 children are born 56 each year with SCD, with millions of people currently affected across the globe (2,3), 57 about two-thirds of them in Africa (ref). SCD has been recognized as a public health 58 issue and a neglected problem by several key agencies, including the United Nations (UN) and the World Health Organization (WHO)(4). The chronic morbidity associated 59 with SCD may lead to an increased socioeconomic burden and requires long-term 60 quality of care (5) SCD is commonly associated with the development of 61 hypogonadism, but there is controversy regarding its etiology, mechanisms, and 62 63 clinical implications (5).

Hypogonadism is characterized by impaired testicular function, which may affect spermatogenesis and/or testosterone synthesis. Usually the diagnosis of hypogonadism requires identification of low serum testosterone (T) levels. Individuals with low T levels may be asymptomatic or present with a worse metabolic status, reduced energy, diminished physical performance, fatigue, depression, reduced motivation, poor concentration, infertility, reduced sex drive, erectile dysfunction and increased rates of all-cause mortality (6–8).

Although the development of androgen deficiency is currently considered multifactorial, male hypogonadism has been classically classified as hypergonadotropic (primary) or hypogonadotropic (secondary) according to its etiology (9). More recently a new clinical variant of hypogonadism defined as defined

5

75 as compensated hypogonadism has been proposed, which is characterized by 76 normal T and elevated LH levels. These authors suggested that compensated 77 hypogonadism represents a distinct clinical state, which warrants monitoring despite 78 its unknown etiology and consequences (8). Compensated hypogonadism has also 79 been reported in 3% of patients with male infertility, with similar outcomes of those 80 with primary hypogonadism (9).

81 Multiple theories have been proposed in attempts to explain the 82 hypogonadism related to SCD. Zinc deficiency, socioeconomic factors, constitutional variables, and repetitive vaso-occlusive episodes in the testes and pituitary, are 83 84 possible explanations though the definite cause remains unknown. Vaso-occlusion is the most widely accepted theory as recurrent microinfarctions in patients with SCD 85 86 are commonly found in other organs and systems (10). Few studies have been designed to evaluate hormonal abnormalities in men with SCD and a more precise 87 understanding is yet to be accomplished (11). 88

As studies evaluating detailed hormonal profiles in men with SCD are lacking, the aim of this study was to estimate the prevalence of hypogonadism in men with SCD and to characterize its etiology using a more comprehensive classification.

92

6

94 MATERIALS AND METHODS

95

- 96 Study design and population
- 97

98 This was a cross-sectional study involving 34 men with SCD aged 18 or older 99 who were followed up at a local SCD referral center between January and December 2019. Men with a history of cryptorchidism, testicular tumors, testicular or inguinal 100 surgery, or with acute onset of testicular at the time of the interview were excluded. A 101 structured questionnaire, including sociodemographic (age, sex, self-reported 102 103 race/color) and clinical variables (anthropometric measurements, type of hemoglobinopathy, therapy with hydroxyurea or NSAIDs, and the occurrence of 104 priapism), was applied to participants. Anthropometric data (weight and height) were 105 measured and used to calculate the BMI as weight in kilograms divided by height in 106 meters squared (kg/m²). 107

108

109 Hormonal evaluation

110 Blood samples were collected between 7 and 9 a.m. for the determination of total testosterone (TT), free testosterone (FT), LH, and FSH levels, as well as a 111 112 complete blood count and hemoglobin electrophoresis. The methods used for the laboratory tests included: hydrodynamic focusing, flow cytometry, SLS-hemoglobin, 113 and Giemsa microscopy for the complete blood count; electrochemiluminescence 114 assays (Atellica IM® analyzer, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, 115 USA) for the determination of T, LH, and FSH levels; an equation involving TT, sex 116 hormone-binding globulin (SHBG), and the association constant of albumin for T, 117 assuming a fixed albumin concentration of 4.3 g/dL, for the calculation of FT(12); and 118

7

high-performance liquid chromatography (HPLC) and capillary electrophoresis
(Capillarys Hemoglobine) for the quantitation of hemoglobin fractions.

Subjects were classified into four groups according to T and LH levels(13): men were considered to have eugonadism if T \ge 300 ng/dL and LH \le 9.4 mUl/mL; primary hypogonadism was defined as T < 300 ng/dL and LH > 9.4 mUl/mL; secondary hypogonadism as T < 300 ng/dL and LH \le 9.4 mUl/mL; and compensated hypogonadism as T \ge 300 ng/dL and LH \ge 9.4 mUl/mL. FSH levels above 7.8 ng/dL were considered elevated (14).

127 All subjects were verbally and individually approached and provided informed 128 consent. This study was approved by our Research Ethics

129

130 Statistical analysis

131

Quantitative variables were presented as medians and interquartile ranges, while nominal variables were expressed as absolute values, percentages, or fractions. The Mann-Whitney U test was used to compare continuous variables, while the Fisher's test was used to compare categorical variables. A p < 0.05 was considered statistically significant, and 95% confidence intervals were presented as a measure of precision. GraphPad Prism, version 8.0.3, San Diego-CA, USA, was used for data analysis.

139

8

141 **RESULTS**

142

Our sociodemographic data are detailed in **Table 1**. We assessed 34 men with a median age of 33 years [26-41], most of whom had an SS genotype (73.5%) and were black or brown (94.1%). Five (14.7%) of them were on continuous hydroxyurea therapy and all had been medicated with NSAIDs, with ibuprofen being the most commonly used drug.

Fifty percent of patients had LH levels of 5.92 mUI/mL [4.36 – 9.42]. Median FSH levels were 6.01 mUI/mL [4.08 – 8.96], clinical data are detailed in **Table 2**. In our sample, no men were diagnosed with primary hypogonadism, whereas 23 (67.6%) were classified as eugonadal and 2 (5.8%) as having secondary hypogonadism. In addition, compensated hypogonadism was identified in 9 men (26.4%) (**Figure 1**).

We found no differences regarding SCD genotype, anthropometric measurements, or disease severity between eugonadal men and those with compensated hypogonadism. Median FSH levels among men with compensated hypogonadism were significantly higher than among eugonadal men. The proportion of men with FSH levels above 7.8 mUI/mL was significantly higher among those with compensated hypogonadism (p < 0.0001) (**Table 2**).

160

161 **DISCUSSION**

162

Gonadal dysfunction, disturbances of the hypothalamic-pituitary-testicular axis, and the etiology of hypogonadism in patients with SCD are controversial issues, and there are still many uncertainties about the pathophysiology of these conditions and

9

their clinical significance(11). We investigated the prevalence of different types of hypogonadism in men with SCD according to the classification described by Tajar et al (2010) in the EMAS. The prevalence of compensated hypogonadism in our sample of men with SCD was 26.4%, a figure considerably higher than those reported in similar studies, 9.5%(13) and 3%(14), respectively.

171 Tajar at al. (2010) were the first to explore the concept of compensated hypogonadism in a study with 3369 community-dwelling men aged 40-79 years from 172 eight European centers. They also introduced the concept that different 173 hypogonadism categories may present with different clinical features. According to 174 this study, sexual complaints were more frequently reported in cases of primary 175 hypogonadism, whereas isolated physical symptoms such as inability to walk long 176 177 distances or perform brisk physical activity were more common in compensated hypogonadism (8). 178

A retrospective study involving 4173 men with sexual dysfunction by Corona et al., reported that 4.1% of individuals had compensated hypogonadism and were more likely to present with both increased frequency of psychological symptoms, such as anxiety, obsessive-compulsive symptoms, and depression; and increased cardiovascular mortality in comparison to those with primary or secondary hypogonadism. The authors hypothesized that compensated hypogonadism could be a surrogate marker of an underlying disease, rather than a new clinical entity(15).

186 Compensated hypogonadism also appears to be relevant in the elderly. Ucak 187 et al. (2013) conducted a study with 250 men over 70 years of age with compensated 188 hypogonadism and found their T and LH levels to be independently associated with 189 worsening performance of activities of daily living, as well as deteriorating cognitive 190 function, nutritional status, and mood, when compared to healthy controls. The

10

authors concluded androgen and LH levels should be assessed in elderly men, and
those diagnosed with compensated hypogonadism should then undergo a physical
and neuropsychiatric evaluation (16).

The clinical significance of compensated hypogonadism is still poorly understood, but this condition is known to be associated with both aging and an increased frequency of physical symptoms related to testosterone deficiency, but not with sexual complaints, as previously mentioned. These observations and its striking prevalence of 9.5% as reported in the EMAS raise the question of whether this subtype of hypogonadism warrants treatment. In, especially older men, may benefit from the inclusion of LH levels in the initial screening for hypogonadism (17).

Studies about compensated hypogonadism and its etiology are controversial 201 202 and scarce in patients with SCD. Rhodes et al (2009)(18) did not found a statistically significant difference in the testosterone levels of 19 boys with SCD when compared 203 to controls and so they were unable to detect primary hypogonadism. Özen et al. 204 205 (2013)(19) studied 50 Turkish children aged 4 to 18 years and found, among the 35 206 boys included in the sample, one with hypergonadotropic (primary) hypogonadism 207 and 3 with small testes and low testosterone, but with normal luteinizing hormone 208 (LH) levels, suggesting this condition can be either primary or secondary. Abbasi and 209 colleagues (1976)(20) analyzed hormone levels of 14 patients and found elevated concentrations of LH and follicle-stimulating hormone (FSH), as well as low 210 testosterone (T), suggesting primary hypogonadism. Dada and Nduka (1980)(22) 211 212 demonstrated reduced LH, FSH, and testosterone levels in 19 men with SCD, findings suggestive of hypothalamic axis dysfunction (secondary hypogonadism), 213 rather than gonadal failure (primary hypogonadism). Martins et al(23) studied some 214 215 aspects of compensated hypogonadism among 10 men with homozygous SCD.

11

Despite the limited number of patients, the authors referred to compensated hypogonadism as a likely transient condition and considered it a potential state of androgen resistance(23).

219 All subjects with compensated hypogonadism in our sample had FSH levels 220 above 7.8 mU/mL, a threshold previously reported as a predictor of impaired 221 spermatogenesis(24). It is likely that the exocrine compartment might be impaired in while the endocrine compartment might still be enough to sustain appropriate T 222 223 production. A cross-sectional study with 786 Caucasian-European discussed the concept of compensated hypogonadism among infertile subjects. The authors found 224 that this condition had a similar clinical characteristic to those with primary 225 hypogonadism, and both groups had the worst clinical outcomes in terms of impaired 226 227 fertility. While this classification was not designed for the setting of male infertility, it could be useful in clinical practice to indicate impaired spermatogenesis(14). 228

229 It is important to highlight that all men in our sample had history of ibuprofen 230 intake for acute pain episodes. Previous published data indicate a strong association between ibuprofen use and the elevation of LH levels, which might lead to 231 232 compensated hypogonadism. In a randomized controlled trial including 31 men aged 233 18-35 years who received 600 mg of ibuprofen twice daily for 6 weeks, the authors 234 showed ibuprofen use increased LH levels in 23% after 14 days and 33% after 44 days (p = 0.01). They also linked ibuprofen use with a reduction in anti-Müllerian 235 hormone levels and postulated this drug would affect steroidogenesis by inhibiting 236 237 the expression of related genes, thus resulting in HPT axis dysfunction (25). However, this study evaluated solely the impact of short-term course of ibuprofen on 238 hormonal profile, and clinical significance of its effect in the long-term are probably 239 240 negligible.

Although our cohort had only 34 participants, it is one of the largest studies in 241 the scientific literature to evaluate hormonal profiles in men with SCD. We also 242 243 identified a high prevalence of an underreported and poorly understood condition, which might be of clinical significance for monitoring and counseling patients. The 244 245 main limitation of this study is perhaps its cross-sectional design, as no definitive explanation for this condition may be given. In addition, this sample came from a 246 specialized center for patients with SCD and may not represent the general 247 248 population of SCD.

249

13

251 CONCLUSION

253	A high prevalence of compensated hypogonadism was identified in our sample
254	of men with SCD, which may reflect early testicular injury and may progress to
255	permanent dysfunction. It seems to be more prevalent in young men with SCD than
256	in the general population of older men. Vaso-occlusive phenomena, testicular
257	microinfarctions, changes in the testicular microenvironment, long-term or recurrent
258	ibuprofen use, and genetic aspects might be associated with such findings. Although
259	this clinical entity is not completely understood, continuous monitoring might be
260	useful in preventing or anticipating additional clinical deterioration.
261	
262	Disclosure statement
263	The authors report no conflicts of interest.
264	
265	Funding
266	This study received no external funding.
267	
268	Academic affiliation
269	This paper is part of the master's dissertation of Anna Paloma Martins Rocha Ribeiro,
270	Postgraduate Program in Public Health, State University of Feira de Santana.
271	
272	
213	

14

274 **REFERENCES**

- Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med.
 1997;337(9):762–9.
- Wastnedge E, Patel S, Goh MY, Rudan I. The global burden of sickle cell
 disease in children under five years of age: a systematic review and meta-
- analysis. J Glob Health. 2018;8(2):1–9.
- Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global Burden of Sickle
 Cell Anaemia in Children under Five, 2010 2050: Modelling Based on
- Demographics, Excess Mortality, and Interventions. PLoS One. 2013;10(7):1–
 14.
- Mburu J, Odame I. Sickle cell disease: reducing the global disease burden. Int
 J Lab Hematol. 2019;41(February):82–8.
- 287 5. Pleasants S. A moving target: migration has led to an increase in the
 288 occurrence of sickle-cell disease in countries with previously low incidence of
 289 the disorder. Nature. 2014;515(11):1–3.
- Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Bruce J, Chiles KA, et al.
 Evaluation and Management of Testosterone Deficiency: AUA Guideline. J
- Urol [Internet]. 2018; Available from: https://doi.org/10.1016/j.juro.2018.03.115
- 293 7. Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum
- testosterone levels in male hypogonadism□: Why and when to check A
 review. Int J Clin Pract. 2017;(August):1–9.
- Peterson MD, Belakovskiy A, Mcgrath R, Yarrow JF. Testosterone Deficiency ,
 Weakness, and Multimorbidity in Men. Sci Rep [Internet]. 2018;8(5897):1–9.
 Available from: http://dx.doi.org/10.1038/s41598-018-24347-6
- 9. Jungwirth A, Diemer T, Kopa Z, Krausz C, Minhas S, Tournaye H. EAU
- Guidelines on Male Infertility. Vol. 1, European Association of Urology. 2018.
 47 p.
- Li M, Fogarty J, Whitney KD, Stone P. Repeated testicular infarction in a
 patient with sickle cell disease: A possible mechanism for testicular failure.
 Urology. 2003;62(3):551.
- Huang AW, Muneyyirci-Delale O. Reproductive endocrine issues in men with
 sickle cell anemia. Andrology. 2017;5(4):679–90.
- 12. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods

308		for the estimation of free testosterone in serum. J Clin Endocrinol Metab.
309		1999;84(10):3666–72.
310	13.	Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, et al. Characteristics
311		of secondary, primary, and compensated hypogonadism in aging men:
312		Evidence from the European male ageing study. J Clin Endocrinol Metab.
313		2010;95(4):1810–8.
314	14.	Ventimiglia E, Ippolito S, Capogrosso P, Pederzoli F, Cazzaniga W, Boeri L, et
315		al. Primary, secondary and compensated hypogonadism: a novel risk
316		stratification for infertile men. Andrology. 2017;5(3):505–10.
317	15.	Corona G, Maseroli E, Rastrelli G, Sforza A, Forti G, Mannucci E, et al.
318		Characteristics of compensated hypogonadism in patients with sexual
319		dysfunction. J Sex Med. 2014;11(7):1823–34.
320	16.	Ucak S, Basat O, Karatemiz G. Functional and nutritional state in elderly men
321		with compensated hypogonadism. J Am Med Dir Assoc. 2013;14(6):433-6.
322	17.	Lee JA, Kuchakulla M, Arora H, Kulandavelu S, Gonzalez E, Masterson TA, et
323		al. Age induced nitroso-redox imbalance leads to subclinical hypogonadism in
324		Male mice. Front Endocrinol (Lausanne). 2019;10(MAR):1–6.
325	18.	Rhodes M, Akohoue SA, Shankar SM, Fleming I, An A, Yu C, et al. Growth
326		Patterns in Children with Sickle Cell Anemia during Puberty. Pediatr Blood
327		Cancer. 2009;53(4):635–41.
328	19.	Özen S, Ünal S, Erçetin N, Taşdelen B. Frequency and Risk Factors of
329		Endocrine Complications in Turkish Children and Adolescents with Sickle Cell
330		Anemia. Turk J Hematol. 2013;30:25–31.
331	20.	Abbasi AA, Prasad AS, Ortega J, Congco E, Oberleas D. Gonadal Function
332		Abnormalities in Sickle Cell Anemia Studies in Adult Male Patients. Ann Intern
333		Med. 1976;85:601–5.
334	21.	Dada OA, Nduka EU. Endocrine function and haemoglobinopathies: Relation
335		between the sickle cell gene and circulating plasma levels of testosterone,
336		luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males.
337		Clin Chim Acta. 1980;105(2):269–73.
338	22.	Dada O, Nduka E. Endocrine function and haemoglobinopathies: relation
339		between the sickle cell gene and circulating plasma levels of testosterone,
340		luteinising hormone (LH) and follicle stimulating hormone(FSH) in adult males.
341		Clin Chim Acta. 1980;105:269–73.

342	23.	Martins PRJ, De Vito FB, Resende GAD, Kerbauy J, Pereira G de A, Moraes-
343		Souza H, et al. Male sickle cell patients, compensated transpubertal
344		hypogonadism and normal final growth. Clin Endocrinol (Oxf). 2019;91(5):676-
345		82.
346	24.	Barbotin AL, Ballot C, Sigala J, Ramdane N, Duhamel A, Marcelli F, et al. The
347		serum inhibin B concentration and reference ranges in normozoospermia. Eur
348		J Endocrinol. 2015;172(6):669–76.
349	25.	Kristensen DM, Desdoits-Lethimonier C, Mackey AL, Dalgaard MD, De Masi F,
350		Munkbøl CH, et al. Ibuprofen alters human testicular physiology to produce a
351		state of compensated hypogonadism. Proc Natl Acad Sci U S A.

352 2018;115(4):E715–24.

17

354

Variables	n (34)	%
SCD genotype		
Homozygous HbSS	25	73.5
Heterozygous SC/SB-thal	9	26.5
Self-reported race/color		
Black	21	61.8
Brown	11	32.4
Yellow	1	2.9
Indigenous	1	2.9
Hydroxyurea therapy		
No	29	85.3
Yes	5	14.7
NSAIDs use		
No	0	0
Yes	34	100
Education level		
Primary education	7	20.6
Secondary education	20	58.8
Higher education	7	20.6
Occupation		
Active ^a	6	17.7
Inactive	28	82.3
History of priapism		
Yes	18	52.9

355 Table 1 – Sociodemographic and clinical data of men with SCD.

357 **Table 2** – Anthropometric and laboratory data of men with SCD

Variables	Median [p25-p75]*
Weight (kg)	61.5 [56.3 – 67.3]
Height (m)	1.7 [1.64 – 1.75]
BMI (kg/m ²)	21.6 [19.2 – 23.8]
Hemoglobin (g/dL)	9.75 [8.05 – 12.0]
Total testosterone (ng/dL)	582.9 [428.8 – 685.9]
Free testosterone (ng/dL)	9.85 [8.07 – 11.37]
LH (mUI/mL)	5.92 [4.36 – 9.42]
FSH (mUI/mL)	6.01 [4.08 – 8.96]

358 *Data are expressed as medians and interquartile ranges (25th and 75th percentiles)

³⁵⁶

360 Table 3 - Clinical, anthropometric, and laboratory data of eugonadal men with SCD in

		Compensated	
	Eugonadism	hypogonadism	
Variables	(n = 23)	(n = 9)	p value
Homozygous HbSS (%)	16 (69%)	7 (77%)	0.943
Age (years)	34 [27 – 41]	33 [22-41]	0.612
Hydroxyurea therapy (%)	6 (26%)	0 (0%)	0.153
History of priapism (%)	4 (44%)	12 (48%)	0.162
BMI (kg/m²)	21.6 [18.9-23.9]	21.7 [19.7-22.9]	0.991
Hemoglobin (g/dL)	9.8 [8.5-12.1]	9.3 [7.6-11.4]	0.331
FSH (mUI/mL)	5.37 [3.7-6.3]	9.5 [9.0-23.8]	< 0.0001*
FSH > 7,8 (%)	5 (21.7%)	9 (100%)	< 0.0001*

361 comparison to those with compensated hypogonadism.

362 *Statistically significant differences

363 BMI: body mass index; FSH: follicle-stimulating hormone; LH: luteinizing hormone.

